NCT02386800 2026-03-16
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
Clinical Trials
8 trialsNCT03610971 2026-01-29
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06768476 2026-01-16
AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT03117751 2025-12-05
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT02131584 2025-10-27
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03286530 2025-07-14
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting